UroGen Pharma Ltd. - Ordinary Shares (NQ:URGN)

Performance

52-Week Range 19.9% below 52-week high

40.70

15.8652W Low 50.8152W High

1 Week 6.5% below 1-week high

40.051W Low 43.541W High

UroGen Pharma Ltd. - Ordinary Shares (URGN) traded between $15.86 and $50.81 over the past 52 weeks and last traded at $40.70, 19.9% below its 52-week high. Over the past week it ranged between $40.05 and $43.54.

Past 12 Months

+0.4%

-7.1%

+7.0%

+113.1%

+79.2%

+141.7%

1W +$0.15

1M -$3.11

3M +$2.67

6M +$21.60

YTD +$17.99

1Y +$23.86

URGN was +141.7% over the past year, +113.1% over six months, +79.2% year to date, +0.4% in the last week.

12 Months vs Market

URGN

+141.7%

DIA

+9.7%

SPY

+16.2%

QQQ

+25.3%

IWM

+13.7%

Over the past 12 months URGN returned +141.7% versus DIA (Dow) +9.7%, SPY (S&P 500) +16.2%, QQQ (Nasdaq 100) +25.3% and IWM (Russell 2000) +13.7%.

Volume & Liquidity 0.00× 3-mo avg

Today 4,098 3-mo avg 828.0K

752.8K

760.8K

828.0K

824.5K

YTD

804.4K

858.6K

URGN most recently traded 4,098 shares against a 3-month average daily volume of 828.0K.

More News

UroGen Pharma to Present at Upcoming Investor Conferences

September 02, 2026

UroGen Announces Strategic Collaboration and Investment Agreements with IntraGel to Access Biodegradable Sustained-Release Gel Platform and Expand Oncology Pipeline

August 20, 2026

UroGen Submits NDA for UGN-103, an Investigational Treatment of Recurrent LG-IR-NMIBC

August 17, 2026

Urogen Pharma (NASDAQ:URGN) Nears 52-Week High on Minervini Trend Template and High Growth Momentum Screen ↗

July 09, 2026

Via Chartmill

UROGEN PHARMA LTD (NASDAQ:URGN) Flawlessly Passes Minervini Trend Template with Accelerating Growth ↗

June 08, 2026

Via Chartmill

UroGen (URGN) Q2 2026 Earnings Call Transcript ↗

August 12, 2026

UroGen Reports $50.4 Million of ZUSDURI Revenue and Provides Second Quarter 2026 Financial Results and Highlights

Urogen Pharma Q2 Earnings Call Highlights ↗

August 05, 2026

Via MarketBeat

August 05, 2026

UroGen Pharma to Report Second Quarter 2026 Financial Results on Wednesday, August 5th, 2026

July 29, 2026

UroGen Receives New U.S. Patent Allowance Expected to Provide Protection into July 2044 for ZUSDURI™ and UGN-103

July 15, 2026

UroGen's Chief Medical Officer Sold $400,000 in Stock After a 191% Run ↗

July 12, 2026

UroGen Announces FDA Clearance of the IND for UGN-501, an Investigational Next-Generation Oncolytic Virus for Non-Muscle Invasive Bladder Cancer

July 08, 2026

Is UroGen Pharma a Stock to Sell After Its Chief Medical Officer Let Go of 10,000 Shares? ↗

June 30, 2026

Is UroGen Pharma a Stock to Sell After Its Chief Medical Officer Unloaded 5,222 Shares? ↗

June 14, 2026

UroGen Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

June 05, 2026

UroGen Announces Agreement Resolving Patent Litigation Relating to JELMYTO® (mitomycin) for pyelocalyceal solution

June 02, 2026

UroGen Pharma to Present at the Goldman Sachs 47th Annual Global Healthcare Conference

June 01, 2026

What to Know About This Fund's $6.6 Million UroGen Sale After a 600% Stock Surge ↗

May 23, 2026

Why a Biotech Fund Opened a New $6 Million Position in Vir Amid a 99% Stock Rally ↗

May 23, 2026

UroGen Reports 94.5% Six-Month Duration of Response in Phase 3 UTOPIA Trial, Advancing UGN-103 Toward Potential Approval in Recurrent Low-Grade Intermediate-Risk NMIBC

May 15, 2026

ZUSDURI Median Duration of Response Still Not Reached with 64.5% 36-month Duration of Response in the Pivotal ENVISION Trial

May 13, 2026

UroGen (URGN) Q1 2026 Earnings Transcript ↗

May 07, 2026

UroGen Pharma to Present at Upcoming Investor Conferences

May 07, 2026